NCT00027690View on ClinicalTrials.gov

Gefitinib in Treating Patients With Persistent or Recurrent Endometrial Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

June 30, 2002

Primary Completion Date

September 30, 2004

Study Completion Date

July 31, 2013

Conditions
Recurrent Uterine Corpus Carcinoma
Interventions
DRUG

Gefitinib

Given orally

OTHER

Laboratory Biomarker Analysis

Correlative studies

Trial Locations (1)

19103

Gynecologic Oncology Group, Philadelphia

All Listed Sponsors
collaborator

Gynecologic Oncology Group

NETWORK

lead

National Cancer Institute (NCI)

NIH

NCT00027690 - Gefitinib in Treating Patients With Persistent or Recurrent Endometrial Cancer | Biotech Hunter | Biotech Hunter